EU MDR Clinical Investigation Pathway: Sponsor Obligations, EUDAMED, and Timelines
A complete guide to medical device clinical investigations under EU MDR Articles 62-82. Learn about sponsor obligations, EUDAMED submissions, and ISO 14155.
Navigating the Clinical Frontier of the EU MDR
Under Regulation (EU) 2017/745 on medical devices (EU MDR), the threshold for clinical evidence has risen dramatically. Manufacturers can no longer rely solely on clinical equivalence to place high-risk or novel devices on the European market. For implantable and Class III devices, as well as many innovative lower-risk products, conducting a pre-market clinical study is now a mandatory prerequisite for CE marking.
The legal framework for these studies is set forth in Chapter VI (Articles 62 to 82) of the EU MDR, supplemented by the detailed provisions of Annex XV. This framework governs the clinical investigation lifecycle from application and ethical approval to clinical conduct, safety reporting, and publication of results. Crucially, the European Commission’s Medical Device Coordination Group (MDCG) has issued MDCG 2021-6 Rev.1 (updated late 2023), providing the authoritative interpretation of when these rules apply and how they differentiate from other clinical activities.
Navigating this pathway requires a thorough understanding of sponsor obligations (including the mandatory designation of an EU legal representative for non-EU sponsors), the single submission mechanism via the EUDAMED Clinical Investigations Module, and the strict competent-authority review timelines.
This guide provides a comprehensive, operational manual for sponsors planning and executing an EU MDR clinical investigation. We map the entire Articles 62-82 lifecycle, translate the MDCG 2021-6 applicability test, detail safety reporting under Article 80, compare the device clinical pathway against the drug Clinical Trials Regulation (CTR), and outline how the ISO 14155 standard integrates with the MDR legal mandates. For a side-by-side comparison of how this EU pathway stacks up against the FDA IDE (21 CFR Part 812), Saudi SFDA, and Health Canada investigational-device regimes, see our investigational device rules compared guide; this article goes deep on the EU procedure itself.
When is a Clinical Investigation Required Under MDR?
The first decision a manufacturer must make is determining whether a proposed clinical study is legally classified as an MDR clinical investigation, a post-market clinical follow-up (PMCF) study, or a non-interventional study. This distinction is critical because it dictates the level of regulatory oversight, submission requirements, and timelines.
The MDCG 2021-6 Applicability Flowchart
To determine the classification of your study, you must apply the regulatory tests defined in MDCG 2021-6 Rev.1. The guidance classifies studies into three main pathways, visualized in the decision tree below:
┌────────────────────────────────────────┐
│ Is the study conducting clinical │
│ testing on human subjects? │
└───────────────────┬────────────────────┘
│
Yes ┌────────────┴────────────┐ No
▼ ▼
┌───────────────────────────────────┐ ┌────────────────────────┐
│ Is the device CE-marked and used │ │ OUT OF SCOPE OF │
│ within its intended purpose? │ │ CLINICAL REGULATION │
└─────────────────┬─────────────────┘ └────────────────────────┘
│
No ┌─────────────┴─────────────┐ Yes
▼ ▼
┌───────────────────────────┐ ┌──────────────────────────────────────────┐
│ ARTICLE 62 CLINICAL │ │ Will subjects be exposed to additional │
│ INVESTIGATION │ │ invasive or burdensome procedures? │
│ - Requires competent │ └────────────────────┬─────────────────────┘
│ authority approval │ │
│ - EUDAMED submission │ Yes ┌────────────┴────────────┐ No
│ - Full safety reporting │ ▼ ▼
└───────────────────────────┘ ┌───────────────────────────┐ ┌───────────────────────────┐
│ ARTICLE 74(1) PMCF │ │ STANDARD PMCF STUDY │
│ CLINICAL INVESTIGATION │ │ - Notify competent │
│ - Requires notification │ │ authority if national │
│ - EUDAMED registry entry │ │ law requires │
│ - GCP monitoring │ │ - Document in PMCF Plan │
└───────────────────────────┘ └───────────────────────────┘
1. Pre-Market Clinical Investigation (Article 62)
An investigation designed to collect primary clinical data to establish the safety, performance, and clinical benefit of a device for the purpose of CE marking. This path applies if:
- The device is not yet CE-marked.
- The device is CE-marked but is being tested for a new clinical indication, anatomical location, patient population, or intended use that falls outside its current CE mark scope.
All Article 62 investigations must be submitted through EUDAMED, approved by competent authorities and ethics committees, and conducted under the strictest Good Clinical Practice (GCP) requirements.
2. Post-Market Clinical Follow-Up (PMCF) Investigation (Article 74(1))
If the device is already CE-marked and is being used within its approved intended purpose, but the study protocol exposes subjects to additional invasive or burdensome procedures (e.g., additional blood draws, extra imaging scans, or diagnostic tests that go beyond standard clinical care), the study falls under Article 74(1).
While Article 74(1) studies are less heavily regulated than pre-market trials, the sponsor must still notify the concerned Member States at least 30 days before the study begins, and the trial remains subject to safety reporting and monitoring requirements.
3. Non-Interventional PMCF Study (Standard PMCF)
If the CE-marked device is used within its intended purpose, and the patients are only subjected to standard clinical procedures with data collected retrospectively or via standard questionnaires (no additional invasive or burdensome tests), it is a standard PMCF study.
These studies do not require competent-authority approval under Chapter VI of the MDR (though national ethical approvals and GDPR consent forms still apply). For details on designing compliant surveys for this path, refer to our guide on PMCF survey design.
Sponsor Obligations Under MDR Articles 62-82
A "sponsor" under the MDR is any individual, company, institution, or organization which takes responsibility for the initiation, management, and setting up of the financing of the clinical investigation. Sponsors bear the ultimate legal and operational responsibility for the study's conduct.
The EU Legal Representative (Article 62(2))
For international medical device companies, one of the most critical legal mandates is the requirement for a local representative.
[!IMPORTANT] Under Article 62(2), if the sponsor of a clinical investigation is not established in the European Union, they must designate a natural or legal person established in the Union as their legal representative.
This legal representative is not merely a postal address or a regulatory consultant; they are the official addressee for all competent-authority communications and carry joint and several legal liability for the conduct of the investigation and compliance with the MDR. The legal representative must:
- Verify that the sponsor has met all MDR application requirements.
- Serve as the physical contact point for inspections.
- Be legally empowered to represent the sponsor in regulatory actions.
- Ensure that the investigator site agreements, insurance certificates, and clinical protocols are maintained and accessible.
Informed Consent (Article 63)
The protection of human subjects is paramount. Article 63 details the strict requirements for obtaining and documenting informed consent. Consent must be obtained before any study-specific procedures are performed, and it must be:
- Given in writing, signed, and dated by both the subject (or their legally designated representative) and the investigator.
- Preceded by a comprehensive information session using clear, non-technical language that is appropriate for the subject's level of understanding.
- Documented along with the subject's right to withdraw from the investigation at any time without penalty or loss of medical care.
Protection of Vulnerable Populations (Article 64)
The MDR introduces specific, heightened protections for vulnerable groups, adding strict conditions under which clinical investigations on these populations may be conducted:
- Minors (Article 64): Clinical investigations on minors may only be conducted if the investigation is essential to validate data obtained on adults, directly benefits the minor cohort, and poses minimal risk. Consent must be signed by the parents or legal guardians, and the minor must be provided with information appropriate to their age and maturity.
- Incapacitated Subjects: Consent must be obtained from their legally designated representative. The investigator must demonstrate that the study cannot be conducted on non-incapacitated subjects.
- Pregnant or Breastfeeding Women: The investigation must offer a direct benefit to the woman or her fetus/child, or, if there is no direct benefit, it must be shown that the research will contribute to clinical findings of significant value for pregnant or breastfeeding women and cannot be performed on other populations.
Quality and Monitoring Obligations
Sponsors must implement a robust quality management system for their clinical trials. This includes:
- Appointing an Independent Monitor: The sponsor must designate a qualified, independent monitor to visit each investigational site regularly. The monitor verifies that the trial is conducted in accordance with the protocol, GCP, and the MDR, and reports findings directly to the sponsor.
- Providing Insurance/Indemnity: The sponsor must secure appropriate insurance or indemnity coverage to compensate subjects for any injury or death resulting from participation in the clinical investigation, in accordance with national laws.
Single Submission Via the EUDAMED Clinical Investigations Module
The EU MDR aims to streamline the clinical trial application process across the Union. Under the prior Medical Device Directive (MDD) regime, sponsors had to submit separate applications to the competent authority of every single Member State where they intended to run sites. The MDR replaces this fragmented system with a unified, single electronic submission.
The Single-Submission Workflow
The central tool for this process is the EUDAMED Clinical Investigations and Performance Studies Module.
Sponsor creates Single Application in EUDAMED
│
▼
EUDAMED generates a Union-wide Single Identification Number (SIN)
│
▼
System routes application to all selected Member States automatically
│
├───────────────────────────────┤
▼ ▼
Member State A (C.A.) Member State B (C.A.)
│ │
Ethics Committee Review Ethics Committee Review
│ │
▼ ▼
Validation & Assessment Validation & Assessment
│ │
▼ ▼
National Decision A National Decision B
Through EUDAMED, the sponsor enters the clinical study data and uploads the required documentation. The system automatically generates a Union-wide Single Identification Number (SIN). This SIN must be used in all subsequent communications regarding the study.
Once submitted, EUDAMED routes the application to the competent authorities and ethics committees of all concerned Member States. This enables coordinated reviews and facilitates the Voluntary Coordination Procedure (VCP) under Article 78, where a single coordinating Member State leads the assessment on behalf of all participating nations.
The Transitional Workaround (Playbook for the EUDAMED Delay)
Although the MDR entered into force in 2021, the EUDAMED Clinical Investigations Module has experienced delays in achieving full mandatory status.
Until the European Commission declares EUDAMED fully functional (which is subject to staged rollout acts), sponsors must follow the national transition guidelines:
- National Submissions: Sponsors must submit their clinical investigation applications directly to the national competent authorities of each concerned Member State using national portals (such as the CCMO portal in the Netherlands or BfArM portal in Germany).
- Standardized Forms: Member States utilize standardized templates based on MDCG guidance (such as the MDCG clinical investigation application form) to harmonize the information requested.
- Local Registries: Sponsors must obtain national registration numbers and subsequently upload their study information to EUDAMED once the module becomes mandatory or is used voluntarily by the local state.
Competent-Authority Assessment Timelines Under Article 70
Article 70 of the MDR establishes strict, legally mandated timelines for the validation and assessment of clinical investigation applications by competent authorities. Understanding these timelines is crucial for project planning, as competent-authority reviews are a major driver of clinical trial start dates.
The review process is divided into two distinct phases:
┌────────────────────────────────────────────────────────────────────────┐
│ 1. VALIDATION PHASE (Up to 15 Days) │
│ - Competent Authority checks if the application is complete and within │
│ the scope of the MDR. │
│ - Clock stops if CA requests missing information (sponsor has 10 days).│
└───────────────────────────────────┬────────────────────────────────────┘
▼
┌────────────────────────────────────────────────────────────────────────┐
│ 2. ASSESSMENT PHASE (Up to 45 Days) │
│ - CA conducts technical, clinical, and ethical evaluation. │
│ - Assessment period can be extended by up to 20 days for expert │
│ consultation. │
│ - Clock stops if CA issues questions (sponsor has a defined response │
│ window, typically 10-20 days). │
└───────────────────────────────────┬────────────────────────────────────┘
▼
┌────────────────────────────────────────────────────────────────────────┐
│ 3. NATIONAL DECISION │
│ - Approved, Approved with Conditions, or Rejected. │
└────────────────────────────────────────────────────────────────────────┘
1. The Validation Phase (Articles 70(1) & 70(3))
Upon receiving the application, the competent authority has 10 days to validate whether the device falls under the MDR scope and whether the application dossier is complete (including all Annex XV Section 2 requirements, investigator brochures, clinical investigation plans, and insurance certificates).
If the application is incomplete, the authority notifies the sponsor, who typically has 10 days to submit the missing information through the portal. Once the missing details are received, the competent authority has an additional 5 days to validate the application. The official validation date is the date on which the competent authority confirms the application is complete.
2. The Assessment Phase (Article 70(7))
The competent authority must assess the application within 45 days from the validation date. During this time, they evaluate:
- The clinical design, safety, and performance parameters.
- The risk-benefit ratio of the device and investigation design.
- The qualifications of the clinical investigators and suitability of the sites.
- Compliance with the ethical principles of the Declaration of Helsinki.
The competent authority can extend this 45-day period by an additional 20 days if they need to consult external experts or scientific panels.
Clock Stops and Questions
If the competent authority has questions or requires modifications to the protocol, they will issue a formal request. This triggers a clock stop.
The review timeline is paused until the sponsor submits a formal response. If the sponsor fails to respond within the designated timeframe (usually 10 to 30 days depending on the Member State), the application is deemed withdrawn.
Substantial Modifications (Article 75)
If a sponsor needs to make a substantial modification to an ongoing clinical investigation (defined as a change that is likely to have a significant impact on the safety, health, or rights of the subjects, or on the robustness or reliability of the clinical data), they must follow the procedure in Article 75:
- The sponsor notifies the concerned Member States within one week of the decision, via the EUDAMED electronic system (Article 73), including an updated version of the relevant Annex XV documentation with the changes clearly identified.
- Under Article 75(3), the sponsor may implement the modification no earlier than 38 days after the notification date — unless a Member State has refused it (on grounds such as those in Article 71(4), or for public health, subject safety, or public policy reasons) or an ethics committee has issued a negative opinion valid for that Member State. The 38-day period is therefore a standstill window, not a separate assessment clock.
- Certain modifications that would alter the suitability of the investigation to demonstrate safety, performance, or clinical benefit may be refused and require a new clinical investigation application rather than a modification.
Safety Reporting Obligations Under Article 80
Safety reporting during a clinical investigation is one of the sponsor's most critical regulatory duties. The MDR establishes a strict regime for reporting adverse events to ensure that patient safety is monitored in real-time across the EU.
Definitions of Reportable Events
Under Article 80, the sponsor must record and report:
- Serious Adverse Event (SAE): Any adverse event that led to death, serious deterioration in the health of the subject (resulting in life-threatening illness/injury, permanent impairment, or hospitalization), or fetal distress/death.
- Device Deficiency: Any inadequacy in the identity, quality, durability, reliability, safety, or performance of an investigational device, including malfunction, use errors, or inadequacy in information supplied. Crucially, device deficiencies must be reported if they might have led to a serious adverse event if suitable action had not been taken, if intervention had not occurred, or if circumstances had been less fortunate.
Timeline for Safety Reporting
The detailed reporting timelines are set by the European Commission's MDCG 2020-10/1 guidance (the authoritative safety-reporting guidance for MDR Article 80), which establishes two tiers:
- Imminent-risk events: Any reportable event that indicates an imminent risk of death, serious injury, or serious illness and requires prompt remedial action for other patients, users, or subjects must be reported immediately, and no later than 2 calendar days after the sponsor becomes aware of the event (or of new information about an already-reported event).
- All other reportable events: All other reportable SAEs, device deficiencies that could have led to an SAE, and new findings must be reported immediately, and no later than 7 calendar days after the sponsor becomes aware. In some cases, a different periodicity may be agreed between the participating national competent authorities and the sponsor based on the investigation's design and the pathology under study.
[!NOTE] These 2- and 7-day windows apply to clinical investigation safety reporting under MDR Article 80 / MDCG 2020-10/1. They are distinct from the separate MDR vigilance timelines for post-market serious incidents (Article 87), which use a 2-day, 10-day, and 15-day tiered structure, and from the 7- and 15-day SUSAR timelines under the drug Clinical Trials Regulation (EU) 536/2014.
Sponsors must use the standardized MDR Clinical Investigation Safety Reporting Form (usually available as an Excel sheet from the European Commission) and submit it via EUDAMED or the designated national portals.
Device vs. Drug Trial Safety Reporting
It is essential to recognize that safety reporting under the MDR differs significantly from the Clinical Trials Regulation (EU) 536/2014 (CTR) for medicinal products. The table below outlines these structural differences:
| Parameter | Medical Device Trial (EU MDR Article 80) | Drug Trial (CTR 536/2014) |
|---|---|---|
| Foundational Concept | Focuses on Serious Adverse Events (SAEs) and Device Deficiencies that could lead to an SAE. | Focuses on Suspected Unexpected Serious Adverse Reactions (SUSARs). |
| Deficiency Tracking | Mandatory to report performance issues or use errors (Device Deficiencies) that could have caused harm. | No direct equivalent for reporting non-harmful drug product deviations under the safety portal. |
| Causality Assessment | Evaluates the relationship between the event and both the device and the investigational procedure. | Evaluates the relationship between the event and the investigational medicinal product (IMP). |
| Reporting Tool | Submitted via EUDAMED (or national Excel forms during transition) directly to competent authorities. | Submitted via the Clinical Trials Information System (CTIS) to the European Medicines Agency (EMA). |
Sponsors conducting combined drug-device studies (such as drug-eluting stents or companion diagnostics) must implement dual-reporting procedures to satisfy both Article 80 and the CTR requirements. For a deeper look at companion diagnostics and IVD clinical pathways, refer to our comprehensive guide on clinical evaluation reports and clinical equivalence assessment MDCG 2020-5.
Harmonised Conduct: The Role of ISO 14155
While the EU MDR defines the legal pathway, competent-authority timelines, and reporting forms, it does not specify the operational methodology for conducting the trial. For this, sponsors must turn to the harmonised standard: ISO 14155:2020 - Clinical investigation of medical devices for human subjects — Good clinical practice.
Compliance with ISO 14155 is the primary route to demonstrating compliance with the GCP requirements mandated in MDR Annex XV.
How ISO 14155 Integrates with the MDR
ISO 14155 provides the technical framework for the lifecycle of a study:
- Clinical Investigation Plan (CIP): Defines the structure, endpoints, statistical methods, and investigator roles. Under MDR, the CIP must meet the requirements of Annex XV Chapter II.
- Investigator’s Brochure (IB): Assembles all pre-clinical and historical clinical data for the device. The MDR mandates this document in Annex XV Section 2.
- Quality Assurance & Monitoring: Outlines the duties of the clinical research monitors and the audit procedures.
- Ethical Considerations: Codifies the protection of subjects in alignment with the Declaration of Helsinki.
Sponsors must ensure that their clinical trial protocols, monitoring plans, and data management systems are designed to meet both the operational criteria of ISO 14155 and the legal boundaries of the MDR. For a deep dive into the specific monitoring and quality audits required under the standard, see our detailed guide on the ISO 14155 clinical investigation standard and our baseline for GCP for medical device clinical trials.
Action Plan for Sponsors
If you are preparing to run a medical device clinical investigation in the EU, follow this roadmap to ensure compliance and avoid review delays:
- Perform an Applicability Check: Use the MDCG 2021-6 flowchart to verify whether your study is pre-market (Article 62), post-market interventional (Article 74(1)), or standard PMCF.
- Appoint an EU Legal Representative: If your organization is based outside the EU, contract with a qualified EU legal representative early, as they must review and sign the application files.
- Draft the Dossier to Annex XV Standards: Write the Clinical Investigation Plan (CIP) and Investigator's Brochure (IB) in strict alignment with Annex XV and ISO 14155.
- Prepare for Transitional Submissions: Check the current registration requirements of each target Member State to determine if they accept voluntary EUDAMED submissions or require national portal filings.
- Establish Safety Workflows: Set up safety databases and train clinical trial monitors on the 2- and 7-day Article 80 reporting windows defined in MDCG 2020-10/1.
Frequently Asked Questions
Does a non-EU sponsor need an EU legal representative for an MDR clinical investigation?
Yes. Under Article 62(2), a sponsor established outside the EU must designate a natural or legal person established in the European Union as their legal representative. This representative is legally responsible for ensuring the study is compliant and shares joint and several liability with the sponsor.
Is ISO 14155 mandatory for an MDR clinical investigation?
While the MDR does not explicitly name ISO 14155 in the text of the regulation, it is the harmonised standard for Good Clinical Practice (GCP) for medical devices in the EU. Notified Bodies and competent authorities treat compliance with ISO 14155 as the default method to satisfy the GCP requirements outlined in MDR Annex XV.
How does an MDR clinical investigation differ from a clinical trial under the Clinical Trials Regulation?
MDR clinical investigations are governed by Regulation (EU) 2017/745 and focus on device safety, performance, and device deficiencies. Drug trials are governed by Regulation (EU) 536/2014 (CTR) and focus on drug safety, efficacy, and suspected unexpected serious adverse reactions (SUSARs). The submission portals (EUDAMED vs CTIS) and safety reporting workflows are distinct.
What happens if a competent authority rejects a clinical investigation application?
If an application is rejected, the sponsor receives a formal notification detailing the reasons for refusal. The sponsor can address the deficiencies and submit a new application (which will receive a new Single Identification Number) or appeal the decision through national administrative procedures in the respective Member State.
Are clinical investigation results made public under the MDR?
Yes. To ensure clinical transparency, the MDR requires sponsors to submit a summary of the clinical investigation report and a layperson summary to EUDAMED within one year of the end of the investigation (or within 3 months if the study was terminated early). This information is public, subject to redactions for commercial confidentiality.
References
- Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (EU MDR). EUR-Lex.
- Medical Device Coordination Group (MDCG). MDCG 2021-6 Rev.1 - Regulation (EU) 2017/745 - Questions and Answers regarding clinical investigations. published December 2023. EC Public Health.
- BSI Compliance Navigator. Clinical Investigations and the MDR: Sponsors and Legal Representatives. BSI Blog.
- CCMO Netherlands. Clinical Investigations with Medical Devices (MDR). CCMO Portal.
- ISO 14155:2020 Clinical investigation of medical devices for human subjects — Good clinical practice. ISO Organization.